Cytokine Therapy
Cytokine Therapy - Related Videos
12:58
Expression of Exogenous Cytokine in Patient-derived Xenografts via Injection with a Cytokine-transduced Stromal Cell Line
0 Views •
Cited by 2 •
2017
Described here is a method for producing exogenous cytokine in patient-derived xenograft (PDX) mice via weekly intraperitoneal injection of a cytokine-transduced stromal cell line. This method broadens the utility of PDX and provides the option for transient or sustained exogenous cytokine delivery in a multitude of PDX models.
10:24
Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System
0 Views •
Cited by 23 •
2015
The goal of this protocol is to manufacture pathogen-specific clinical-grade T cells using a bench-top, automated, second generation cell enrichment device that incorporates a closed cytokine capture system and does not require dedicated staff or use of a GMP facility. The cytomegalovirus pp65-specific-T cells generated can be directly administered to patients.
02:57
Assessing Antiviral Cytokine Production in Response to Viral Infection
0 Views •
2026
Source: Zhang, J., et al. Dissecting Innate Immune Signaling in Viral Evasion of Cytokine Production. J. Vis. Exp. (2014)This video demonstrates the process of infecting murine fibroblast cells with herpesvirus and monitoring the resulting antiviral cytokine release and gene expression. It outlines key steps, including viral infection, media collection for cytokine quantification, and cell harvesting for gene expression analysis.
08:32
Dissecting Innate Immune Signaling in Viral Evasion of Cytokine Production
0 Views •
Cited by 2 •
2014
We describe a protocol to measure the antiviral cytokine production in mice infected with a model herpesvirus, murine gamma herpesvirus 68 (γHV68) that is closely-related to human Kaposi’s sarcoma-associated herpesvirus (KSHV) and Epstein-Barr virus (EBV). Utilizing genetically modified mouse strains and mouse embryonic fibroblasts (MEFs), we assessed the antiviral cytokine production both in vivo and ex vivo. “Reconstituting” the expression of innate immune components in knockout embryonic...
04:49
A Multiplex Bead-Based Immunoassay to Quantify Multiple Cytokine Targets
0 Views •
2025
This video demonstrates a multiplex bead-based immunoassay for quantifying multiple cytokine targets in a sample. A mixture of distinct microspheres conjugated to cytokine-specific antibodies is used to bind the cytokines present in the sample. Streptavidin-tagged reporters are immobilized on the bound-cytokines using biotinylated detection antibodies. Flow cytometry identifies the bound cytokines based on the unique sizes and internal fluorescence intensities of the microspheres, while the...
FAQs
Binding to a matching receptor initiates intracellular signaling in immune or tumor cells. Those signals can activate cytotoxic lymphocytes, change cellular proliferation, or promote tumor-cell death. Because receptor expression and downstream responses differ among cell types, the same cytokine may produce distinct effects in immune cells and tumors, influencing both therapeutic activity and selectivity.
Dose and delivery affect which cells encounter the cytokine and how strongly they respond. These variables can alter immune activation, effects on tumor-cell growth, and inflammatory consequences. Consequently, researchers must evaluate treatment conditions alongside the cytokine itself, since changing exposure patterns may shift the balance between antitumor activity and unwanted inflammatory toxicity.
Interferons and interleukins can engage different receptor systems and trigger distinct intracellular responses. Their signaling may stimulate cytotoxic lymphocytes, modify proliferation, or contribute to tumor-cell death, depending on the responding cell and tumor context. Comparing these cytokine classes helps researchers identify which immune or tumor-cell response best supports a particular antitumor strategy.
The tumor microenvironment contains interacting cellular and signaling conditions that can shape cytokine responses. As a result, an agent that activates immune defenses in one setting may have a different effect on tumor cells or surrounding immune cells elsewhere. Considering this context helps explain variable outcomes and guides efforts to improve treatment selectivity.
Cytokine therapy provides a way to study how immune signaling can regulate both host defense and tumor behavior. Its effects may include activating cytotoxic lymphocytes, changing proliferation, or promoting tumor-cell death. These outcomes allow cancer researchers to investigate antitumor immunity while examining how inflammatory signaling influences treatment performance within the tumor setting.
Cytokines may support other immunotherapies by strengthening or reshaping antitumor immune activity. Their signaling can provide additional stimulation to cytotoxic lymphocytes or modify responses within the tumor environment. Combination strategies therefore focus on complementary effects, while accounting for dose, delivery, tumor context, and the possibility that intensified immune signaling may increase inflammatory toxicity.
Cytokines act on signaling networks that regulate immune defense, inflammation, and cell growth, so beneficial antitumor effects can occur alongside unwanted inflammatory responses. Cancer research therefore examines how to direct activity toward tumors or useful immune populations while limiting excessive inflammation. Improving this balance is essential for developing more effective and tolerable treatment strategies.